TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1781562
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg CD p.o. on the evening before the operation, followed by 25 mg p.o. in the morning
Study: 1781562
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg F p.o. on the evening before the operation, followed by 1 mg p.o. in the morning
Study: 7004995
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no corticosteroid therapy)
Study: 27117175
Drug: Study Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Group (SG, circulating the prime with 40 g albumin for 5 minutes before CPB)
Study: 27117175
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG, receiving 40 g human albumin 5 minutes after the initiation of CPB)
Study: 24976416
Drug: Skimmed milk
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk (500 mL/d) for 1 year
Study: 24976416
Drug: Semi-skimmed milk
Normalized name: Calcium fortified semi-skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-skimmed milk (500 mL/d) for 1 year
Study: 19770669
Drug: Simvastatin/ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/ezetimibe (10 mg simvastatin and 10 mg ezetimibe, once a day)
Study: 19770669
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg, once a day)
Study: 12119507
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PSL) >12.5 mg/day for at least 1 year
Study: 12119507
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (BDP) alone
Study: 4061902
Drug: Intravenous lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lidocaine, 1.5 mg/kg
Study: 16464208
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel (Regranex) plus good wound care (GWC)
Study: 7956719
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg single dose or 250 mg twice daily)
Study: 7956719
Drug: Midecamycin acetate
Normalized name: Midecamycin acetate
DrugBank: Midecamycin (DB13456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midecamycin acetate (600 mg b.i.d.)
Study: 29843203
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection group (Group S, n = 63)
Study: 24307656
Drug: High-dose intragraft
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intragraft adenosine infusion (200 μg/min; total dose = 2,000 μg)
Study: 18490173
Drug: Fast track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast track treatment regimen (preoperative fasting 2h, patient controlled epidural analgesia)
Study: 18490173
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment regimen (preoperative fasting 6h, patient controlled analgesia)
Study: 18490173
Drug: Fast track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast track treatment regimen
Study: 18490173
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment regimen
Study: 8967601
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg midazolam p.o. (Dormicum)
Study: 6379784
Drug: Non-specific immunotherapy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific immunotherapy (aqueous suspension of heat killed mycobacterium smegmatis, administered subcutaneously once a month)
Study: 6379784
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no other treatment following excision)
Study: 29965991
Drug: Ultrasound-guided peripheral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided peripheral nerve block (PNB) with 10 mL prilocaine 1% and 10 mL ropivacaine 0.2%
Study: 26902832
Drug: Yukmijihwang-tang (YMJ)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yukmijihwang-tang (YMJ) administered at 3g, three times per day for 8 weeks
Study: 26902832
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 3g, three times per day for 8 weeks
Study: 25158865
Drug: DPP4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitor (sitagliptin 200 mg by mouth)
Study: 17216336
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg CS‐706 once daily
Study: 17216336
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg CS‐706 once daily
Study: 7793169
Drug: Gemeprost (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost (1 mg) as a vaginal suppository in 12 hour intervals
Study: 7793169
Drug: Dinoprost (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprost (500 micrograms) in a tylose-gel in 6-8 hour intervals
Study: 2193840
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg cyclopenthiazide/8.1 mmol sustained release potassium
Study: 842487
Drug: Urea supplementation
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea supplementation (4 g of nitrogen)
Study: 842487
Drug: Opaque-2 corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opaque-2 corn (6 g of nitrogen)
Study: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation 5 μg/d
Study: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation 10 μg/d
Study: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation 6.3 μg/d
Study: 21270380
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation 0 μg/d (placebo)
Study: 19011511
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposome infusion (VSLI) at 2.0 mg/m infused over 1 hour every 2 weeks (one cycle)
Study: 19011511
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposome infusion (VSLI)
Study: 9020419
Drug: 0.5% morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% morphine HCl nasal challenge
Study: 9020419
Drug: Workplace trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workplace trial with bronchodilator and placebo
Study: 9020419
Drug: Nasal and
Normalized name: Nasal and Sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal and bronchial challenge with 0.5% morphine HCl
Study: 1411923
Drug: Cis platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis platinum (Cis PII) 100 mg/m2 i.v. followed by 6 Gy irradiation in two fractions on days 3 and 5, five cycles at 21 days interval.
Study: 3871251
Drug: Triple sulfonamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple sulfonamide combined with either phenoxymethyl penicillin or benzathine and procaine penicillin G (IM)
Study: 20953168
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL lidocaine plus dummy lingual injection (LB)
Study: 20953168
Drug: 0.9 mL
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mL lidocaine (LBL)
Study: 20953168
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL articaine plus dummy lingual injection (AB)
Study: 20953168
Drug: 0.9 mL
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mL articaine (ABL)
Study: 17437743
Drug: Anemia in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia in subjects with CKD (baseline GFR ≤60 ml/min/1.73 m²)
Study: 12225796
Drug: PEG‐rHuMGDF (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF (various doses)
Study: 12225796
Drug: PEG‐rHuMGDF (minimally
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF (minimally effective dose)
Study: 12179676
Drug: Oxytocin administered
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administered at the end of the second stage of labor
Study: 7784413
Drug: Cabergoline (CAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (CAB 0.5‐1 mg twice weekly)
Study: 7784413
Drug: Bromocriptine (BRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (BRC 2.5‐5 mg twice daily)
Study: 2353171
Drug: Delayed-release, enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release, enteric-coated tablet of mesalazine (Claversal)
Study: 25906561
Drug: Acupuncture (resuscitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (resuscitation and tranquilization technique) applied to specific acupuncture points (Shenting, Shuigou, Sishencong, Baihui, Feng-chi) once daily, 6 times a week for 8 weeks.
Study: 25906561
Drug: Deanxit (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deanxit (oral administration, 1 tablet in the morning and lunchtime each day for 8 weeks).
Study: 380610
Drug: Meptazinol 100
Normalized name: meptazinol 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 100 mg/70 kg
Study: 380610
Drug: Pentazocine 60
Normalized name: pentazocine 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 60 mg/70 kg
Study: 30961631
Drug: Non-surgical weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical weight loss therapy (hypocaloric diet -500 kcal/day)
Study: 29389246
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide (Az; 10 mg/kg) plus intravenous dobutamine (Dob) infusion (2-5 μg·kg-1·min-1)
Study: 29389246
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (Indo; 100 mg)
Study: 27113231
Drug: Internet-delivered exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered exposure-based cognitive behaviour therapy (ICBT) for 12 weeks
Study: 24662777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ezetimibe and simvastatin (n = 24)
Study: 20803425
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day fish oil capsule (with 180 mg EPA and 120 mg DHA, totaling 300 mg n-3 fatty acids)
Study: 12610804
Drug: Intermittent cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclical etidronate therapy (ICET)
Study: 10333100
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with three different treatment parameters
Study: 373071
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive tablets)
Study: 26051575
Drug: Ginger essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger essential oil inhalation
Study: 21310101
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate and benzydamine hydrochloride mouth spray (n = 72)
Study: 16955106
Drug: High-flow treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow treatment (cyclers with high dialysate flow, no manual daytime exchange)
Study: 16955106
Drug: Manual exchange
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Manual exchange treatment (conventional APD with low nightly dialysate flow and one manual daytime exchange)
Study: 15727144
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/week for 8 weeks (R1)
Study: 15727144
Drug: Azithromycin 1500
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1500 mg once upon enrolment (R2)
Study: 15727144
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (R3)
Study: 11516807
Drug: tolterodine 1
Normalized name: tolterodine 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine 1 mg bd
Study: 11516807
Drug: tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine 2 mg bd
Study: 9220215
Drug: Bromfenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac (50 or 100 mg)
Study: 9220215
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg/oxycodone 10 mg
Study: 9220215
Drug: Bromfenac (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac (multiple doses)
Study: 9220215
Drug: Acetaminophen/oxycodone (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/oxycodone (multiple doses)
Study: 9220215
Drug: Ibuprofen (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (multiple doses)
Study: 8314271
Drug: sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual captopril 25 mg
Study: 31089955
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment as usual
Study: 27412395
Drug: Electron beam
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electron beam therapy boost (20 Gy in 10 fractions over 2 weeks)
Study: 26175290
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health intervention (3 sessions, booklet, mobile phone text-message reminders)
Study: 24260872
Drug: No postural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postural restrictions after treatment
Study: 18645164
Drug: IGIV-C 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C 10% at 0.2 g/kg
Study: 18645164
Drug: IGIV-C 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C 10% at 0.4 g/kg
Study: 18645164
Drug: IGIV-C 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C 10% at 0.2 g/kg and 0.4 g/kg
Study: 17073201
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ozone treatment)
Study: 23696155
Drug: Payment card
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Payment card format (monthly and yearly variants)
Study: 22231607
Drug: Statin medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin medication use
Study: 22231607
Drug: Statin medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin medication use (multivariate-adjusted)
Study: 18235048
Drug: Baseline fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline fasting plasma glucose (FPG) >5 mmol/l
Study: 16192543
Drug: Stimulating catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulating catheter (Group S); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Study: 16192543
Drug: Conventional nonstimulating
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nonstimulating catheter (Group C); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Study: 12569298
Drug: Capecitabine (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (2500 mg/m2/day for 14 days every 21 days)
Study: 3075474
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of CsA, azathioprine (AZA), and corticosteroids
Study: 3075474
Drug: Prophylactic combination
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic combination of CsA, corticosteroids, and antilymphocyte globulins (ALG)
Study: 3075474
Drug: CsA dose
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA dose lower than or equal to 5 mg/kg per day
Study: 24948653
Drug: Daily pasture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pasture DM allowance of 3.5% of BW (LO)
Study: 24948653
Drug: Daily pasture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pasture DM allowance of 7.0% of BW (HI)
Study: 23540073
Drug: Topical preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical preparations (novel formulations)
Study: 23540073
Drug: Standard (comparator)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (comparator) formulation
Study: 1535568
Drug: Cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 5 mg b.i.d. for 6 months
Study: 30118368
Drug: m‐AIP (intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐AIP (intrathecal injection of m‐AIP, a specific antagonist of CaMKII)
Study: 30118368
Drug: m‐AIP (postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐AIP (postoperative treatment)
Study: 20708966
Drug: IRIS (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRIS (irinotecan plus oral S-1)
Study: 20708966
Drug: FOLFIRI (folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (folinic acid and irinotecan plus bolus and continuous infusion of fluorouracil)
Study: 369006
Drug: Chronic injection
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic injection group (sclerotherapy with ethanolamine oleate)
Study: 31020334
Drug: Twice-daily concurrent
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily concurrent chemoradiation
Study: 31020334
Drug: Once-daily concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily concurrent chemoradiation
Study: 28431278
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (50IU in solution)
Study: 25599708
Drug: Hyperinsulinemic hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic hypoglycemia (HH) - bolus insulin 0.1 IE/kg i.v.
Study: 25599708
Drug: Hyperinsulinemic euglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemia (HE) - bolus insulin 0.1 IE/kg i.v. and glucose 20% i.v. for 105 min
Study: 23805994
Drug: Lithium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (0.5 to 0.8 mEq/l)
Study: 23805994
Drug: Aripiprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10 or 15 mg)
Study: 21831726
Drug: Liprotamase (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liprotamase (5 capsules per day, one capsule with each meal and snack)
Study: 21831726
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 capsule taken with meals and snacks)
Study: 15583526
Drug: Lifestyle changes,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle changes, antidepressants, alpha‐2 agonists, anticonvulsants, phytoestrogens, dietary supplements
Study: 11744586
Drug: 3-in-1 FNB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 FNB using 30 mL of ropivacaine 0.25%
Study: 11744586
Drug: 3-in-1 FNB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 FNB using 30 mL of ropivacaine 0.5%
Study: 11744586
Drug: 3-in-1 FNB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 FNB using 30 mL of bupivacaine 0.25%
Study: 9378180
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccination in addition to usual EPI vaccines
Study: 9378180
Drug: Usual EPI
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual EPI vaccines (BCG, DTP, OPV, measles, yellow fever)
Study: 28256051
Drug: OASIS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OASIS plus standard therapy
Study: 28256051
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) therapy
Study: 24007452
Drug: mHealth based
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth based remote medication adherence measurement system (mAMS)
Study: 11120525
Drug: 125 mL
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL intravenous fluids per hour
Study: 11120525
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL intravenous fluids per hour
Study: 8250653
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (25 mg of nicotine per 24 hours for 4 weeks, then 1 patch per day for 2 weeks)
Study: 31112512
Drug: Ropivacaine 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 3.75 mg/mL (n=25)
Study: 31112512
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 9 mg/mL) (n=25)
Study: 23724529
Drug: Ankaferd blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankaferd blood stopper (ABS) - 4 ml spray solution (1 ml/puff X 4) applied topically
Study: 23724529
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (0.9% NaCl) - 4 ml applied topically
Study: 15529389
Drug: DHEA 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 200 mg/day for 1 year
Study: 10155090
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab (0.25 mg/kg bolus and 10 micrograms/min infusion for 12 hours)